Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

• 5-HT 2 RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS This invention relates to the treatment of and to compositions containing 5- HT 2 receptor antagonists useful in treating such venous conditions as hemorrhoids, varicose veins, venous insufficiency and wounds.
• 5-HT 2 receptor antagonists useful in treating such venous conditions as hemorrhoids, varicose veins, venous insufficiency and wounds.
• 5-HT2 receptor antagonist can also be administered prophylactically.
• Serotonin or 5-hydrox tryptamine " or 5- HT is a vasoconstrictor and a powerful stimulant of a variety of smooth muscles and nerves.
• a derivative of the amino acid tryptophan, 5-HT is formed predominantly in enterochromaffin or argentaffin cells of the intestinal tract. It is transported in the blood by platelets and is present in the brain and other tissues. Its pharmacological actions result in a variety of responses involving, inter alia, the cardiovascular, respiratory, and gastrointestinal systems, smooth muscles, exocrine glands, carbohydrate metabolism, sensory nerve endings, autono ic ganglia, the adrenal medulla, and the central nervous system.
• Cellular reaction is determined by the type and number of receptors on the outer membrane of the cells. Consequently, one hormone can trigger different responses in different cells because it may have different receptors. Thus, the same hormone that can contract one smooth muscle cell, can also relax a skeletal muscle cell having a different receptor to the same hormone. This is true for 5-HT.
• 5-HT 5-HT
• the antagonists are classified according to their ability to displace the labeled hormone from the receptor in question. Those that can displace it from a particular receptor are said to be antagonists to that receptor. Some antagonists can displace the hormone from one receptor without affecting' its binding to another, and the degree of selectivity can thus be determined.
• the ability of antagonists to antagonize some of the effects of the hormone thought to be related to one receptor or another are examined.
• a suitable example relates to the hormone histamine.
• Some antagonists can antagonize its acid secretory receptors with little or no effect on its lung receptors and thus inhibit acid secretion by the stomach without causing bronchodilatation.
• Other antagonists antagonize histamine's lung effects with almost no activity against its acid secretory effects.
• Biochemical studies are those in which the biochemical effects of the hormone in question can be antagonized selectively by one receptor antagonist or another.
• Serotonin receptors are divided into several classes, one of which is referred to as the 5-HT2 receptor. A complete discussion of such receptors will be found in "The Peripheral Actions of 5-Hydroxytryptamine" edited by John R. Fozard (Oxford University Press, 1989) . Receptors for 5-HT have been classified based on the responses they produce when stimulated by 5- HT. At present four main classes and several subclasses of 5-HT receptors are generally recognized. The four main classes are:
• 5-HT- ⁇ receptorst These receptors appear to mediate the relaxation of smooth muscles and increased heart rate.
• 5-HTn receptors These receptors appear to mediate vasoconstriction and platelet aggregation.
• 5-HT3 receptors These"receptors ⁇ appear to mediate vomiting by action in the central nervous system.
• 5-HT receptor antagonists produce different pharmacological responses depending on the type and location of the 5-HT receptor they antagonize of block. They produce a variety of different responses in the central nervous system. Peripherally, such antagonists can sometimes produce antagonistic responses. This is similar in many respects to the Histamine antagonists. Histamine-1 (H-l) antagonists inhibit bronchioconstriction but have no effect on gastric acid secretion while Histamine-2 (H- 2) antagonists inhibit gastric acid secretion with no effects on the lungs.
• Histamine-1 (H-l) antagonists inhibit bronchioconstriction but have no effect on gastric acid secretion while Histamine-2 (H- 2) antagonists inhibit gastric acid secretion with no effects on the lungs.
• 5-Hydroxytryptamine (5-HT 2 ) receptor antagonists are different from other 5-HT receptor antagonists in many respects in that 5- HT 2 receptor antagonists: a. Antagonize serotonin stimulation of intra-cellular calcium levels via stimulation of phosphoinostiide hydrolysis in smooth muscle, human and rabbit platelets and astrocytes. b. Antagonize serotonin contraction of the canine and human basilar artery while producing no hypotension. c. Antagonize the increased vascular permeability induced by 5-hydroxytryptamine d.
• 5-HT can induce both contraction and relaxation in blood vessels.
• the type of responses produced depends on the type of receptor present. For example, 5-HT 2 receptor stimulation contracted the porcine coronary arteries (Daniel J. Cushing and Marlene L. Cohen, " Comparison of the Serotonin Receptors That Mediate Smooth Muscle Contraction in Canine and Porcine Coronary Artery” J. Pharmacol. Exptl. Therapy. 261, 856 - 862, 1992) but dilated the canine renal artery (Shoji et al.
• 5-HT can mediate both contraction and relaxation in the same tissue (Zeljko S. Radic et al., "Alterations in Serotonergic Receptor Expression in Experimental Vein Grafts;” J. Vascular Surgery 14, 40 - 47, 1991) .
• Tissues respond to hormones only if they possess specific receptors capable of recognizing and interacting with the hormone in question.
• the selective and sometimes opposite responses of different tissues to the same hormone, in this case 5-hydroxytryptamine (5-HT) or serotonin is determined by the type and density of the receptors to the hormone -that exist in the particular tissue. It is not possible to predict the activity of 5-HT receptor antagonists in a particular disease condition unless the tissue involved in that disease is tested. For example, 5-HT will not contract the colon vein of cats or dogs since the colon veins from both animals species have no 5-HT receptors. 5-HT will contract the human colon vein because the human colon vein contains 5-HT2 receptors that mediate contraction, (see example below) .
• 5-HT 2 receptor antagonists are expected to antagonize the increased contraction of the colonic veins induced by 5-HT (shown in the data) and decrease the vascular permeability that mediate the swelling and discomfort of hemorrhoids.
• Other 5-HT receptor antagonists (as S-HT- ⁇ 1A 1B lc ID IP and 3 ⁇ w ⁇ not mediate these effects and are expected to have no beneficial effects in treating hemorrhoids, varicose veins, venous insufficiency and the healing of wounds.
• 5-HT 2 receptor antagonists produce several effects including inhibition of platelet aggregation and decreasing vascular permeability.
• 5-HT 2 receptor antagonist compounds have traditionally been used as anti- anxiety agents, antidepressants, antipsychotics, anti-migraine agents or as modifers of certain other CNS functions.
• 5-HT 2 receptor antagonists do not cause vasodilation in the arteries and do not lower blood pressure. This is shown in the example below where the 5-HT 2 receptor antagonist 2' [2- (1-methyl-2-piperidyl) ethyl] cinnamanilide hydrochloride do not lower blood pressure. This is also exemplified by ritanserine and ICI 169, 269 (Gerard J. Blauw et al. , "Antihypertensive Treatment with Ketanserine Shows No Evidence of Vascular
• Serotonin is not a general endogenous vasoconstrictor. Its effects in the different blood vessels varies depending on the location and size of the vessel in question (P. . van Zwieten et al., "Pharmacological Profile of Antihypertensive" Drugs with Serotonin Receptor and alpha-Adrenoreceptor Activity Drugs 40 (suppl 4) 1 - 8, 1990) .
• Hemorrhoids is a disease of veins not arteries. Drugs that are expected to have beneficial activity in hemorrhoids must be able to antagonize the contractile effects of 5-HT on the colon vein.
• Hemorrhoids is a varicose dilation of veins in the superior or inferior hemorrhoidal plexus, resulting from a persistent increase in venous pressure" (Dorland's Illustrated Medical Dictionary, 25th Edition, .B. Saunders, Philadelphia, 1974) . Hemorrhoids refer to a madd of dilated veins in swollen tissue situated near the anal sphincter. They are believed to result from a persistent increase in venous pressure, which may be due, in part, to a constriction of the large downstream colonic veins. Occlusion due to platelet aggregation and thrombus formation may also contribute to the symptoms of hemorrhoids by interrupting blood flow and increasing blood stasis and tissue congestion. Varicose veins are enlarged, twisted superficial veins. Varicose veins partially result from incompetent venous valves that may be acquired or congenital.
• Venous insufficiency results from increase tone (partial constriction) of the deeper veins (particularly in muscles) which impedes good circulation and results in blood pooling and stasis. This is turn results in pain, tenderness and edema.
• 5-hydroxytryptamine (5-HT or serotonin) is released from the blood platelets when the blood sits around for a long time and is thought to mediate the contraction of the exit veins.
• 5-HT is released from blood platelets causing venous constriction and interfering with good drainage and circulation. Good drainage and circulation are needed for proper and fast healing of the wounds.
• This invention is directed to compositions or medicines useful in treating or preventing such conditions as hemorrhoids, varicose veins, venous insufficiency and wounds.
• a 5- hydroxytryptamine-2 receptor antagonist (5-HT 2 ) to treat an animal or human, in need of such treatment.
• the 5-HT receptor antagonist can also be used prophylactically.
• the 5-HT 2 receptor antagonist is used at an effective therapeutic dose.
• Preferred 5-HT 2 receptor antagonists include 2 ' [2- (1-methyl-2-piperidyl) ethyl] cinnamanilide hydrochloride; 2- [3- [4- (3- chlorophenyl) -1-piperazinyl]propyl-5-ethyl-2,4- dihydro-4- (2-phenoxyethyl) -3H-l,2,4-triazol-3- one hydrochloride,8- [4- [4- (l,2-benzisotriazol-3- yl) -1-piperazinyl]butyl] -8-azaspiro[4,5] decane- 7,9-dione hydrochloride and any mixture thereof.
• the 5-HT 2 receptor antagonist 2' - [2- (l-methyl-2- piperidyl) ethyl] cinnamanilide hydrochloride is disclosed and claimed in U.S. Patent Re. 30, 811 (Dysktra et al. Mead Johnson & Company) .
• the 5- HT 2 receptor antagonist 2- [3- [4- (3- chlorophenyl) -1-piperazinyl]propyl-5-ethyl-2,4- dihydro-4- (2-phenoxyethyl) -3H-l,2,4-triazol-3- one hydrochloride is disclosed in U.S. Patents 4,338,317 and 4,487,773.
• the 5-HT 2 receptor antagonist 8- [4- [4(l,2-benzisotriazol-3-yl) -1- piperazinyl]butyl] -8-azaspiro [4,5] decane-7,9- dione hydrochloride is disclosed in German Patent DE 3,247,530 and U.S. Patent 4,411,901.
• representative 5-HT 2 receptor antagonists were found to produce highly surprising results in blocking the contractile effects of 5-HT on the human colon.
• Human colonic vein rings were isolated from discarded human colon tissue following surgery (colostomy) . The rings were prepared immediately after surgery and were suspended in buffered physiological saline. The contractions produced by the rings in response to the addition of 5-HT in vitro were measured.
• the effects of three selected 5-HT 2 receptor antagonist compounds on antagonizing 5-HT contractile effects were also determined.
• Table A also includes the activities of the three compounds on four receptors to determine receptor selectivity.
• Compound I as used herein has the chemical formula: 2 ' [2- (l-methyl-2- piperidyl)ethyl] cinnamanilide hydrochloride, and has the following structural formula:
• Compound II as used herein has the chemical formula : 2 - [3 - [4- (3 -chlorophenyl) -1- piperazinyl] propyl-5-ethyl-2 , 4-dihydro-4- (2 - phenoxyethyl) -3H-l, 2 , 4-triazol-3 -one hydrochloride, and has the following structural formula : CI
• Compound III as used herein has the chemical formula: 8- [4- [4- (l,2-benzisotriazol-3-yl) -1- piperazinyl]butyl] -8-azaspiro[4,5] decane-7,9- dione hydrochloride, and has the following structural formula:
• the IC-50 is the concentration that inhibits agonist binding to the receptor by 50%.
• the activity is determined as follows: Rings of human colon veins are prepared and hung in a tissue bath. The contractions of the rings are monitored. Adding 5-HT causes the rings to contract. Pre-addition of increasing concentrations of the antagonist result in lesser contractions. The amount of antagonist causing a 50% inhibition of the contractions is then calculated.
• the receptor blocking profile is determined as follows: Labeled 5-HT is mixed with a purified preparation containing the receptor. The amount of labeled material that attaches itself to the receptor and cannot be washed off is calculated. In a series of other similar tubes, the same quantity of labeled 5-HT is mixed with increasing concentrations of the antagonist which will antagonize the binding of 5-HT to the receptor. Decreasing quantities of the labeled material will bind to the receptor. The concentration of the antagonist that inhibits the binding of 50% is then calculated. Table B Activity against 5-HT on the human colon in vitro
• Beagle hounds of either sex weighing 8 - 20 kg were acclimated (18 - 29°C, humidity 30 - 70%) for a minimum of 21 days with automatically controlled illumination (12 hours light/12 hours dark) prior to use.
• Each animal received approximately 300 grams of Purina Lab Canine Diet #5006 daily which was adjusted as needed for each animal to maintain appropriate body weight.
• Husbandry practices and veterinary care were in accordance with the Guide for Care and Use of Laboratory Animals (NIH Publication No. 85 - 23)
• the 5-HT 2 receptor antagonists of this invention may be used topically or systemically, and they may be taken orally, in liquid, powder, table or capsule form; parenterally, by intravenous, subcutaneous, or intramuscular injection; transdermally, topically by direct application in the form of a cream, gel, or ointment; rectally by suppository or enema; or by inhalation therapy.
• the 5-HT 2 receptor antagonists of this invention may be prepared and used in any suitable solid or liquid form, e.g. powder, cream, paste, table, lozenge, gel, chewing gum, solution, suspension, emulsion, salve, aerosol or the like.
• pharmacological agents may be administered in admixture with a pharmaceutically acceptable carrier or a dermatologically acceptable carrier for the topical preparations.
• compositions contain the active ingredient in an amount ranging from less than 1% to over 99%, with the remainder being a pharmaceutically acceptable or dermatologically acceptable solid or liquid carrier, which may contain other conventional excipients.
• carrier and excipients include fillers, binders, flavors, sweetners, bulking and coloring agents, antioxidants, anionic, nonionic, cationic, zwitterionic, and amphoteric surface active detergents, sudsing, dispersing and emulsifying agents, buffering and pH adjusting agents, water and organic solvents, humectants, thickeners, preservatives, stabilizers, mold release agents, disintegrates, anti-distingegrants, lubricants and the like.
• the topical compositions typically contain from 0.1 to 20 weight % of a 5-HT 2 receptor antagonist. Preferably, they contain from 0.5 to 10 weight %. More preferably, from 1 - 5 weight %.
• Transdermal compositions typical contain from 0.1 to 20 weight % of a 5-HT 2 receptor antagonists. Preferably, they contain from 0.5 to 10 weight %. More preferably, from 1- 5 weight %.
• Suppositories typically contain from 0.1 to 20 weight % of a 5-HT 2 receptor antagonist. Preferably, they contain from 0.5 to 10 weight %. More preferably, from 1- 5 weight %.
• Wound dressings typically contain from 0.1 to 20 weight % of a 5-HT 2 receptor antagonist. Preferably, they contain from 0.5 to 10 weight %. More preferably, from 1- 5 weight %.
• compositions of this invention consist of sufficient material to provide a dose of from 0.05 - 10 mg. per kg. of body weight, more suitably 0.2 - 6 mg/kg body weight. These compositions may be taken 1 - 3 times daily or as needed until the pain or symptoms of the conditions have subsided.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Cardiology (AREA)
• Dermatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (10)

Applications Claiming Priority (1)

Publications (1)

Family

ID=25225434

Family Applications (1)

Country Status (11)

Cited By (3)

Families Citing this family (12)

Citations (4)

Family Cites Families (20)

• 1992
  • 1992-01-09 US US07/818,389 patent/US5266571A/en not_active Expired - Lifetime
• 1993
  • 1993-02-19 DE DE69333413T patent/DE69333413T2/de not_active Expired - Lifetime
  • 1993-02-19 CA CA002156481A patent/CA2156481C/en not_active Expired - Fee Related
  • 1993-02-19 WO PCT/US1993/001485 patent/WO1994018958A1/en active IP Right Grant
  • 1993-02-19 AU AU37748/93A patent/AU678149B2/en not_active Expired - Fee Related
  • 1993-02-19 EP EP93906979A patent/EP0684816B1/en not_active Expired - Lifetime
  • 1993-02-19 PT PT93906979T patent/PT684816E/pt unknown
  • 1993-02-19 ES ES93906979T patent/ES2215990T3/es not_active Expired - Lifetime
  • 1993-02-19 KR KR1019950703438A patent/KR100278522B1/ko not_active IP Right Cessation
  • 1993-02-19 AT AT93906979T patent/ATE258789T1/de active
  • 1993-02-19 DK DK93906979T patent/DK0684816T3/da active
• 1995
  • 1995-08-07 US US08/512,235 patent/US5605902A/en not_active Expired - Lifetime

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events